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Abstract
Introduction: The World Health Organization recommends that countries conduct two phase evaluations of HIV
rapid tests (RTs) in order to come up with the best algorithms. In this report, we present the first ever such
evaluation in Uganda, involving both blood and oral based RTs. The role of weak positive (WP) bands on the
accuracy of the individual RT and on the algorithms was also investigated.
Methods: In total 11 blood based and 3 oral transudate kits were evaluated. All together 2746 participants from
seven sites, covering the four different regions of Uganda participated. Two enzyme immunoassays (EIAs) run in
parallel were used as the gold standard. The performance and cost of the different algorithms was calculated, with
a pre-determined price cut-off of either cheaper or within 20% price of the current algorithm of Determine +
Statpak + Unigold. In the second phase, the three best algorithms selected in phase I were used at the point of
care for purposes of quality control using finger stick whole blood.
Results: We identified three algorithms; Determine + SD Bioline + Statpak; Determine + Statpak + SD Bioline, both
with the same sensitivity and specificity of 99.2% and 99.1% respectively and Determine + Statpak + Insti, with
sensitivity and specificity of 99.1% and 99% respectively as having performed better and met the cost requirements.
There were 15 other algorithms that performed better than the current one but rated more than the 20% price.
None of the 3 oral mucosal transudate kits were suitable for inclusion in an algorithm because of their low
sensitivities. Band intensity affected the performance of individual RTs but not the final algorithms.
Conclusion: We have come up with three algorithms we recommend for public or Government procurement
based on accuracy and cost. In case one algorithm is preferred, we recommend to replace Unigold, the current tie
breaker with SD Bioline. We further recommend that all the 18 algorithms that have shown better performance
than the current one are made available to the private sector where cost may not be a limiting factor.
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Background
Rapid tests (RTs) for HIV antibody in blood and saliva are
being promoted for HIV diagnosis in resource limited set-
tings in order to improve the quality of service delivery,
acceptability and uptake of HIV testing and counselling
(HTC) [1, 2]. The advantage of RTs compared with en-
zyme immunoassays (EIA) is the simplicity in use and the
quick turn-around time of results leading to improve-
ments in service delivery including prevention, care and
treatment. Unlike EIAs, RTs do not require much use of
instrumentation and with good training can be used by
non-laboratory staff in remote centres. In the past few
years, there has also been an increasing interest in the use
of HIV self-testing (HIVST) to help increase testing cover-
age and a number of countries already have HIVST pol-
icies [3]. HIVST is where an individual, who wants to
know his or her HIV status collects his/her specimen, tests
it and interprets the results, often in private. Most HIVST
is by the use of oral tests that use saliva and currently one
HIVST kit, OraQuick In-Home HIV Test is approved by
the USA Food and Drug Administration (FDA) [4]. Fur-
thermore, there are now 4th generation RTs that allow de-
tection of infection in the earlier phase of infection due to
the ability to detect HIV antigen which appears earlier
than antibodies after infection. The challenge is that some
of these 4th generation RTs are still lagging behind, largely
due to their inadequate performance so far especially in
detecting acute infections [5, 6], and only the Determine
HIV 1/2 Ag/Ab Combo is currently approved by the FDA.
The Joint United Nations Programme on HIV/AIDS
(UNAIDS) 90–90-90 targets aim at 90% of people know-
ing their HIV status, 90% of those positive receiving
ARVs and 90% of those receiving ARVs suppressing viral
load to below detection by 2020 [7]. The attainment of
this will require unprecedented roll out of HTC. Nations
will need to ensure HTC expansion to meet these targets
but also to provide quality HIV testing as a priority.
In Africa, various RT kits are currently on market and
different algorithms are being used, but evaluation of
these tests especially in field settings of the general pop-
ulations has been limited [8]. In addition, most HIV test
kits have been evaluated as individual kits and not test-
ing algorithms. The global practice is that each country
must select and standardize their testing algorithms
based on local situations e.g. costs, storage issues, hu-
man resource, infrastructure, service demand etc. [9].
In Uganda, HIV rapid testing began in 1990 using Capil-
lus HIV-1/HIV-2 (Cambridge Diagnostics) and since then
various kits have been used [10, 11], it was in 2006 that a
national testing algorithm of Determine HIV 1/2, HIV-1/2
Statpak and Uni-Gold HIV was introduced but without
extensive evaluation. Other algorithms have been pro-
posed [12] but their evaluations were based on limited kits
and without following the recommended World Health
Organization (WHO) and US Center for Disease Control
and Prevention (CDC) guidelines [8, 13]. One other chal-
lenge with the current national algorithm is related to the
interpretation of results that show weak positive (WP)
bands which have led to low specificity and positive pre-
dictive value (PPV) [14]. With more kits on market, there
is therefore a need to evaluate them, come up with better
algorithms for the country and make recommendations
on the observed WP bands. The objectives of this study
therefore were to determine the appropriate HIV RT and
recommend 2–3 algorithms to be used in Uganda.
Specific objectives were 1) To assess the performance of
eleven blood and three oral fluid based rapid tests and
come up with best algorithms. 2) To determine the pro-
portion of HIV positive RTs with WP bands but which
eventually turn out negative on confirmation using EIA. 3)
To ascertain the inter-reader agreement in HIV diagnosis
using RTs. 4) To assess the correlation of finger stick
blood HIV results and those obtained by use of plasma.
Method
The study followed the CDC/WHO guidelines for RT evalu-
ations [13]. It was a two phase study where phase I was a
laboratory-based evaluation to determine test performance
and to identify 3 algorithms that were later evaluated in
phase II at the point of care (POC). Phase II used a finger
prick by laboratory and non-laboratory staff and quality
control (QC) at the National Reference Laboratory (NRL)
performed on 10% of the negative and 100% of positive sam-
ples using the algorithms used at the POC. For oral based
kits, both laboratory and field testing took place in phase I.
A total of eleven blood based kits were evaluated namely:
Determine HIV1/2, HIVSav 1&2 rapid serotest, Acon HIV
1/2/0 Triline, Uni-gold HIV, SD Bioline HIV 1/2 3.0, First
Response HIV 1–2. O, Carestart HIV 1.2.O, Doublecheck
Gold HIV 1&2, HIV 1/2 StatPak, Medinostics HIV 1/2
Gold rapid screen and Insti HIV antibody. The three oral
transudate kits evaluated were OraQuick HIV-1/2, Calypte
Aware HIV-1/2 OMTand Chembio DPP HIV1/2.
These were selected from the United States Agency for
International Development (USAID) list of approved HIV
kits. These kits had undergone evaluation and approval by
either FDA or another stringent regulatory approval for
Canada, European Union Japan or USAID. From this list,
kits that did not meet the study’s selection criteria of storage
(2–300 C), specimen type to use serum, plasma and whole
blood, ease of use (that included number of steps, ease of
reading the test, nature of specimen collection and whether
no special equipment was required), and shelf life (at least
12 months) were excluded. Other reasons for kits exclusion
were limited information and not for our Ugandan market.
Before the study, the study team was trained on the
standard operating procedures (SOPs) and on the protocol.
Site visits were made in preparation for and during the
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study to monitor progress. Ten milliters (mls) of venous
blood was collected in ethylenediaminetetraacetic acid
(EDTA) (5 ml), the anticoagulant preferred by most test kit
manufacturers and serum separating tubes (SST 5 ml). The
blood based kits were evaluated using EDTA whole blood
while oral kits were evaluated using oral transudate by
swabbing of participants gums to obtain sample. Each kit
was tested following the instructions in its insert. The
serum from the SST tubes was used for confirmatory test-
ing using 2 EIAs i.e. Vironostika HIV Uni-form II plus O
and Murex HIV-1.2.O run in parallel as the gold standard.
In-house cut off values used by CDC Uganda were used
(UVRI NRL QC/quality assurance (QA) report 2000).
These cut offs had been established after validation of these
EIAs using local samples in order to increase their specifi-
city without compromising sensitivity. The EIAs were done
at Medical Research Council/UVRI Uganda at Entebbe and
at Rakai Health Sciences Program (RHSP) in Rakai with
technicians blinded to the RT results.
Testing of the blood based kits was done by laboratory
technicians at the laboratories at each site while oral
transudate kits were evaluated by nurse counsellors at
the respective sites. In order to address objective num-
ber two, results were scored as weakly reactive or WP
when the intensity of the test band was weaker than the
control band but in the calculation of kit performance,
all test bands were interpreted as positive regardless of
intensity as required by the manufacturer. All results
were read independently by two operators at three sites
in order to assess inter-observer agreement.
The sensitivity (Se), specificity (Sp), negative predictive
value (NPV), PPV false positive rate (FPR) and false nega-
tive rate (FNR) of each kit was calculated using the EIAs as
gold standard. The performance criteria for the desirable al-
gorithms were then established. A minimum sensitivity of
99.0% was set for the screening kits and a minimum specifi-
city of 98.0% was set for the confirmatory and tie breaker
kits [2]. Combinations of all kits that met the above criteria
were then made and the performance (Se, Sp, PPV, NPV,
FPR, FNR) and cost of the different algorithms calculated.
The cost of the kits was determined using the HIV Test
kits listed in the USAID Source and Origin Waiver [15]. We
also compared this with the WHO procurement prices for
2013. The cost of each algorithm was estimated using the
formula described in Appendix A using the average national
prevalence of 7.3% [16]). The technical team of the ministry
proposed a new algorithm had to be cheaper or within 20%
price of the current algorithm. The price of the algorithm be-
ing used at the time was about 1.50 US$ per test. Results
were double entered and consistency checks done at UVRI.
Study sites and participant selection
Seven sites, covering the four different regions of Uganda,
participated in the phase I evaluation namely; − AIDS
Information Centre (AIC) Kampala and MRC/UVRI Kya-
mulibwa (Central), Rakai Health Sciences Program (RHSP)
and Mbarara Regional Referral Hospital (Western), St.
Mary’s Lacor Hospital, Gulu (Northern), The AIDS Support
Organization (TASO) Jinja and TASO Soroti (Eastern), see
site locations in Fig. 1. Participants already known to be HIV
positive were recruited after collection of the 200 HIV nega-
tive samples at each site. Four sites AIC, TASO Entebbe,
TASO Masaka and Lacor Hospital participated in phase II.
Statistical methods
Sample size
The study followed the CDC/WHO guidelines for HIV test
evaluation [13] which recommend that a test evaluation ex-
ercise should have a minimum of approximately 200 HIV-
positive and 200 HIV negative specimens to provide 95%
confidence intervals of less than ±2% for both the estimated
sensitivity and specificity. This number was considered at
each of the 7 study sites (Rakai, Kyamulibwa, AIC, Tororo,
Jinja, Mbarara and Gulu) to give a targeted enrolment of
2800 individuals (1400 HIV negatives and 1400 HIV
positives). Consideration of this sample size per region was
decided to give an opportunity to investigate whether there
are environmental or other local factors that could affect test
performance, especially the reported weak positive bands.
Samples included and those excluded in the analysis
A total of 200 HIV positive and 200 HIV negative indi-
viduals from each of the sites involved were eligible.
However, the analysis only considered those individuals
whose samples were in quantities that would allow for
all the tests under evaluation together with EIA tests to
be performed. Those that did not have enough samples
were excluded from the analysis. The analysis also
excluded those that had discordant EIA tests.
Dates of sample collection for phase I
The samples were drawn from October 2010 to December
2012. More specifically, for Lacor, this was 4th October
2010 – 11th February 2011. MRC Kyamulibwa, 7th Octo-
ber 2010 - 5th October 2011; Mbarara: 14th October 2010
- 17th December 2010; RHSP: 12th October 2010 - 16th
February 2011. AIC-Kampala: 23rd November 2010 - 15th
April 2011; Jinja: 4th January 2011 - 13th December 2012
and Soroti: 13th September 2011 - 9th May 2012.
Dates of sample collection for phase II
TASO Masaka was 5th February 2015 to 11th March
2015; TASO Entebbe 25th February 2015 to 30th March
2015; Lacor Hospital 18th February 2015 to 20th April
2015 and AIC was 13th April 2015 to 29th June 2015.
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To assess specificity, sensitivity, negative and positive
predictive values
STATA 12 was used to calculate the sensitivity, specifi-
city PPV and NPV. These values were calculated by first
taking the WP results as positive and then removing the
WP results from the calculation to determine the influ-
ence of WPs on false positive rates.
Receiver operating curves (ROC)
Though our major interest was Se, Sp, NPV and PPV, we
used the STATA command roccomp to compare the ROC
generated using the three best algorithms to the current na-
tional algorithm in use (Determine + Statpak + Unigold).
Developing an algorithm
Data were analyzed to determine the performance of indi-
vidual tests. Kits that passed the above sensitivity criteria
were considered as screening tests while kits that passed
the specificity criteria were considered as confirmatory tests
or as a tie breaker when evaluating an algorithm. For the
algorithm evaluation, the study considered a serial testing
model whereby specimens were considered as true negative
if they reacted negatively on the first test. For specimens re-
active on the first test a confirmatory test would be consid-
ered. If specimens were concordantly positive by the two
assays, they were considered as true-positives. For discord-
antly reactive sera, the third test kit or tie breaker results in
the algorithm would be considered as definitive.
To determine the proportion of HIV positive RTs with WP
bands but which eventually turn out negative on EIA
confirmation
In order to assess whether the WP scores were equally
distributed in the four geographical regions for each RT,
cross tabulation of the blood RT results against the EIA
tests were generated indicating the percentage of WPs
that returned positive or negative EIA results.
To ascertain the inter-reader variability using RTs
In order to determine the inter-reader variability of the
RTs, two persons independently interpreted each test re-
sult, and the reader variability, expressed as percentage
Fig. 1 Map of Uganda showing the four regions and site locations where the phase I testing was performed. Source: http://d-maps.com/
carte.php?num_car=4025&lang=en but with the study sites added
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of sera for which different readers interpret test results
differently was calculated for each RT.
Quality assurance
This study was conducted under a rigorous QA program
which included among others, training of personnel, devel-
opment of SOPs, coordination of sample transport and stor-
age, equipment maintenance and proficiency testing.
Samples were given unique identifiers in all the laboratories.
Phase II In the second phase, the three algorithms selected
in phase I were used in the field, at the POC for purposes
of QC. Finger stick whole blood testing was done at three
sites where two different algorithms per site were used.
Matching plasma from all HIV positive specimens and 10%
of HIV negative specimens were retested at the NRL at
UVRI using the same testing algorithms as at the POC.
Before initiation of phase II, there was a change in the
manufacture of Determine HIV1/2 from Abbott to Alere
Medical Co Ltd., Japan. Although the kit composition
did not change, we compared the performance of both
kits and showed these two kits were not different in
their performance (results not included).
Results
Figure 2 shows the logic framework for phase I and II.
Phase I
In phase I, a total of 2800 participants were enrolled, with
400 samples tested at each of the 7 centers. However, the kits
were evaluated using samples from 2746 participants i.e. 392
from AIC; Mbarara 387; Kyamulibwa 392; Rakai 399; Lacor
384; Jinja 395 and Soroti 397 participants. Those missing
had either EIA test results that were discordant or samples
collected were insufficient for the Gold standard test.
First Response and Carestart had more WP results;
they scored 36.7% and 36% respectively. These were
followed by Acon Triline (27.5%) and HIVSav (25.7%).
StatPak (3.0%) followed by Determine (6.2%), Unigold
(6.4%), Insti (11.4%) and SD Bioline (12.5%) had the least
WP scores. All kits had a WP score in all participating
centers (Table 1). Eastern (58.8%) followed by Central
Fig. 2 The logic framework for phase I, the laboratory-based evaluation and phase II at the point of care
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Uganda (53.8%) had significantly higher proportion of
samples testing WP on any kit compared to Western
(43.9%) and Northern Uganda (47.7%), table not shown.
For all the kits evaluated, the exclusion of samples with
WP bands improved the specificity and PPVs.
Table 2 shows the performance of the blood based kits
with WP taken as positive and after removal of the WP
(No WP). Determine had the highest sensitivity of 99.3%
and 99.2% with and without WP respectively. Insti had the
second best sensitivity of 99.2% and 98.9% with and without
WP respectively. Medinostics had the best specificity of
99.1 and 99.8 with and without WP respectively. Unigold
had the best specificity when WP were taken as positive
and 9 RTs had specificity of ≥90 after removal of WPs.
Table 3 shows the performance of the oral kits. Aware
had the highest sensitivity of 97% when WP were included
and 96.4 after removal of WP. On the other hand, Ora-
quick had the highest sensitivity of 96.5% when WPs were
excluded which increased to 96.8% when WP were in-
cluded. Oraquick and Aware had the highest specificity of
98.5% when WPs were included and the highest specificity
of 99.2% when WPs were excluded.
After sensitivity and specificity analyses, it was ob-
served that the best test kits that could be used as
screening tests were Determine and Insti (with best sen-
sitivity before and after removing results with WP
bands). However, it was also observed that Medinostics
had the “best” PPV of 99.1% before and 99.6% after the
removal of results with a WP band. Medinostics also
had the highest specificity of 99.1% before and 99.8%
after removal of results with a WP band.
It was therefore decided to compare algorithms where De-
termine and Insti were the screening tests. Combinations of
all kits that met the above criteria were then made and the
performance (sensitivity, specificity, PPV, NPV, FPR, FNR)
and cost of the different algorithms calculated. None of the 3
oral mucosal transudate kits were suitable for inclusion in an
algorithm evaluation because of their low sensitivities.
Even though HIVsav passed the criteria for a screening
kit, all algorithms in which it was included were elimi-
nated because their sensitivities were lower than the
current algorithm.
Based on the results in Tables 4, 18 algorithms had a per-
formance better than the current national algorithm. The
three algorithms indicated in Tables 4 and 5, 1) Determine
+ SD Bioline + Statpak; 2) Determine + Statpak + SD Bio-
line and 3) Determine + Statpak + Insti which performed
better than the current algorithm and met the cost require-
ments are recommended as the new national algorithms.
Algorithms containing Medinostics were all removed be-
cause the kit could not be procured by the study team.
Receiver operating curves
The ROC observed showed no statistically significant
differences between the three selected algorithms and
the currently used one. Determine + Statpak + SDBio to
Determine + Statpak + Unigold, (p = 0.31); Determine +
SDBio + Statpak to Determine + Statpak + Unigold,
(p = 0.31); Determine + Statpak + Insti to Determine +
Statpak + Unigold (p = 0.25). The ROC area for the three
new algorithms was marginally wider when compared to
that generated for the current national algorithm.
Inter-reader variability
Analyses done at three sites, Rakai, Jinja and Soroti
showed that the inter-reader variability between two
Table 2 Summary of the kit performance for the blood based kits
Rapid Test Kit Sensitivity Specificity PPV NPV FPR FNR
With WP
as POS
After
removal
of WP
With WP
as POS
After
removal
of WP
With WP
as POS
After
removal
of WP
With WP
as POS
After
removal
of WP
With WP
as POS
After
removal
of WP
With WP
as POS
After
removal
of WP
Determine 99.3 99.2 89.6 99.0 90.1 99.0 99.2 99.2 10.4 1.0 0.7 0.8
HIVSav 99.1 98.2 97.6 99.6 97.5 99.2 99.1 99.1 2.4 0.4 0.9 1.8
Acon 99.0 97.7 97.5 99.7 97.4 99.3 99.0 99.0 2.5 0.3 1.0 2.3
Unigold 98.9 98.7 98.6 99.6 98.6 99.5 98.9 98.9 1.4 0.4 1.1 1.3
SD Bioline 99.0 98.6 98.3 99.7 98.2 99.6 99.0 99.0 1.7 0.3 1.0 1.4
First Response 99.0 96.7 93.4 98.9 93.4 96.4 98.6 98.6 6.6 1.1 1.0 3.3
Carestart 99.0 97.0 92.1 98.4 92.3 95.2 99.0 99.0 7.9 1.6 1.0 3.0
Doublecheck 98.7 97.8 96.2 99.4 95.9 98.8 98.8 98.8 3.8 0.6 1.3 2.2
Statpak 98.8 98.7 98.4 99.5 98.3 99.4 98.9 98.9 1.6 0.5 1.2 1.3
Medinostics 98.9 98.1 99.1 99.8 99.1 99.6 98.9 98.9 0.9 0.2 1.1 1.9
Insti 99.2 98.9 98.2 99.8 98.9 99.7 99.2 99.2 1.1 0.2 0.8 1.1
Figures represent percentages, with weak positives taken as positives and after their removal
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technicians for all the tests was low, in most cases below
1%, meaning that there were similarities in the interpret-
ation of results (Table 6), exceptions were Jinja where
for Carestart this was 1.26 and 2.01 for Double check
and at Soroti where for Determine this was 2.42% and
for Insti 3.63%. The majority of differences happened
when one reader interpreted a result as having a weak
positive band while another interpreted it as being truly
positive. There were also cases where one reader inter-
preted result as having WP band while the other re-
corded as negative result.
Antigens and technology used
Since it is advisable to use in combinations tests that use
different antigens and technology, this was also exam-
ined for the kits used in the proposed three algorithms
as shown in Table 7. One manufacturer did not provide
this information.
Phase II
In phase II, sites tested a total of 2398 samples. A total of
901 site-specific results were included in the comparison
and were compared to the NRL plasma EIA results.
Table 3 Summary of performance of the Oral kits
Rapid
test kit
Sensitivity Specificity PPV NPV FPR FNR
With WP
as POS
After
removal
of WP
With WP
as POS
After
removal
of WP
With WP
as POS
After
removal
of WP
With WP
as POS
After
removal
of WP
With WP
as POS
After
removal
of WP
With WP
as POS
After
removal
of WP
Oraquick 96.8 96.5 98.5 99.2 98.5 99.1 96.9 96.9 1.5 0.8 3.2 3.5
Aware 97 96.4 98.5 99.2 98.4 99 97.1 97.1 1.5 0.8 3 3.6
DPP 96.4 95.6 98.2 99 98.2 98.7 96.5 96.5 1.8 1 3.6 4.4
Figures represent percentages, with weak positives taken as positives and after their removal
Table 4 Summary of possible algorithms with a performance as good as or better than the currenta
Rank Screening Confirmatory Tie Breaker Sensitivity Specificity PPV NPV FPR FNR Cost per test ($)
1 Insti SDBioline StatPak 99.2 99.4 99.4 99.2 0.6 0.8 4.61
2 Insti Statpak SD Bioline 99.2 99.4 99.4 99.2 0.6 0.8 4.61
3b Determine SD Bioline StatPak 99.2 99.1 99.0 99.2 0.9 0.8 1.43
4b Determine Statpak SD Bioline 99.2 99.1 99.0 99.2 0.9 0.8 1.43
5b Determine Statpak Insti 99.2 99.1 99.0 99.2 0.9 0.8 1.79
6 Determine Insti StatPak 99.2 99.1 99.0 99.2 0.9 0.8 2.05
7 Insti SD Bioline Medinostics 99.1 99.4 99.4 99.1 0.6 0.9 4.61
8 Insti Medinostics SD Bioline 99.1 99.4 99.4 99.1 0.6 0.9 4.61
9 Insti Medinostics Statpak 99.1 99.4 99.4 99.1 0.6 0.9 4.61
10 Insti StatPak Medinostics 99.1 99.4 99.4 99.1 0.6 0.9 4.61
11 Insti Statpak Unigold 99.1 99.4 99.3 99.1 0.6 0.9 4.62
12 Insti Unigold Statpak 99.1 99.4 99.3 99.1 0.6 0.9 4.66
13 Determine Medinostics Statpak 99.1 99.2 99.2 99.1 0.8 0.9 1.43
14 Determine StatPak Medinostics 99.1 99.2 99.2 99.1 0.8 0.9 1.43
15 Determine Medinostics Insti 99.1 99.1 99.1 99.1 0.9 0.9 1.78
16 Determine Insti Medinostics 99.1 99.1 99.1 99.1 0.9 0.9 2.05
17 Determine SD Bioline Insti 99.1 99.0 99.0 99.1 1.0 0.9 1.78
18 Determine Insti SD Bioline 99.1 99.0 99.0 99.1 1.0 0.9 2.05
19c Determine Statpak Unigold 99.1 98.9 98.9 99.1 1.1 0.9 1.50
20 Determine Unigold Statpak 99.1 98.9 98.9 99.1 1.1 0.9 1.54
21 Determine Unigold Insti 99.1 98.9 98.9 99.1 1.1 0.9 1.89
22 Determine Insti Unigold 99.1 98.9 98.9 99.1 1.1 0.9 2.11
aThe order of ranking followed the priority of: 1-sensitivity, 2-specificity, 3-PPV, 4-NPV, 5-FPR, 6-FNR, 7-cost; band bolded are the proposed algorithms;
cIn italics is current algorithm
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Results from AIC, TASO Entebbe and Lacor Hospital
were 100% concordant with the NRL results. Concordance
between results at the TASO Masaka site and NRL was
96.7% with 5 sample results being discordant with EIA re-
sults, 2 for one algorithm (Determine, Statpak, SD Bioline)
and 3 for the other (Determine, Statpak and Insti). Two of
the samples resulted in false negative EIA results while 3
resulted in false positive EIA results. The discordant re-
sults were all from one operator who joined later in the
study and were attributed to inadequate training.
Discussion
This evaluation was necessary because there were indications
that the current national algorithm which has been in use
Table 5 Summary of possible algorithms with a performance as good as or better than the current algorithm ranked in order of costa
Rank Screening Confirmatory Tie Breaker Sensitivity Specificity PPV NPV FPR FNR Cost per test ($)
1b Determine SD Bioline StatPak 99.2 99.1 99 99.2 0.9 0.8 1.43
2 Determine Medinostics Statpak 99.1 99.2 99.2 99.1 0.8 0.9 1.43
3b Determine Statpak SD Bioline 99.2 99.1 99 99.2 0.9 0.8 1.43
4 Determine StatPak Medinostics 99.1 99.2 99.2 99.1 0.8 0.9 1.43
5c Determine Statpak Unigold 99.1 98.9 98.9 99.1 1.1 0.9 1.50
6 Determine Unigold Statpak 99.1 98.9 98.9 99.1 1.1 0.9 1.54
7 Determine SD Bioline Insti 99.1 99.0 99.0 99.1 1.0 0.9 1.78
8 Determine Medinostics Insti 99.1 99.1 99.1 99.1 0.9 0.9 1.78
9b Determine Statpak Insti 99.2 99.1 99.0 99.2 0.9 0.8 1.79
10 Determine Unigold Insti 99.1 98.9 98.9 99.1 1.1 0.9 1.89
11 Determine Insti Medinostics 99.1 99.1 99.1 99.1 0.9 0.9 2.05
12 Determine Insti SD Bioline 99.1 99.0 99.0 99.1 1.0 0.9 2.05
13 Determine Insti StatPak 99.2 99.1 99.0 99.2 0.9 0.8 2.05
14 Determine Insti Unigold 99.1 98.9 98.9 99.1 1.1 0.9 2.11
15 Insti SD Bioline Medinostics 99.1 99.4 99.4 99.1 0.6 0.9 4.61
16 Insti Medinostics SD Bioline 99.1 99.4 99.4 99.1 0.6 0.9 4.61
17 Insti SD Bioline StatPak 99.2 99.4 99.4 99.2 0.6 0.8 4.61
18 Insti Medinostics Statpak 99.1 99.4 99.4 99.1 0.6 0.9 4.61
19 Insti Statpak SD Bioline 99.2 99.4 99.4 99.2 0.6 0.8 4.61
20 Insti StatPak Medinostics 99.1 99.4 99.4 99.1 0.6 0.9 4.61
21 Insti Statpak Unigold 99.1 99.4 99.3 99.1 0.6 0.9 4.62
22 Insti Unigold Statpak 99.1 99.4 99.3 99.1 0.6 0.9 4.66
aThe order of ranking followed the priority of: 1- Cost, 2-sensitivity, 3-specificity, 4-PPV, 5-NPV, 6-FPR, 7-FNR; b In bold are the proposed algorithms;
cIn italics current algorithm
Table 6 Inter reader variability
Rapid test kit Rakai variability (n, %) Jinja variability (n, %) Soroti variability (n, %) Total variability (n, %)
Determine 1, 0.25 1, 0.25 6, 2.42 8, 0.76
HIVSav 3, 0.75 0, 0 0, 0 3, 0.29
Acon Triline 2, 0.50 0, 0 2, 0.81 4, 0.38
Unigold 1, 0.25 1, 0.25 2, 0.81 4, 0.38
SD Bioline 1, 0.25 1, 0.25 2, 0.81 4, 0.38
First Response 3, 0.75 3, 0.76 1, 0.43 7, 0.68
Carestart 0, 0 5, 1.26 0, 0 5, 0.59
Doublechek 0, 0 4, 2.01 0, 0 4, 0.57
Statpak 1, 0.25 3, 0.75 0, 0 4, 0.38
Medinostics 0, 0 1, 0.25 0, 0 1, 0.10
Insti 1, 0.25 2, 0.50 9, 3.63 12, 1.15
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for quite some time may need to be changed. In addition,
several new HIV RTs kits had been developed that may be
better in terms of cost or ease of use if used as part of the na-
tional algorithm. There was also a demand to provide alter-
native algorithms for better service delivery. To achieve this,
we used a more rigorous CDC/WHO recommended evalu-
ation method compared to that which was used earlier.
In our study, the performance of the individual RTs var-
ied. While the sensitivity of all kits except for four was
within that recommended by WHO i.e. (≥ 99%) [17], the
specificity of six kits was lower than the recommended
≥98%, if the WP bands are scored as positive leading to low
PPV. A similar observation was reported before with some
of these kits i.e. Determine and Unigold [14, 18]. There is a
recent study that has also shown poor performance of some
RTs in sub-Saharan Africa than the WHO evaluations [19],
and this was not attributed to weak bands, which were
rarely reported in their study. There are varied reasons for
the performance differences, for instance, it was reported
that the sensitivity of Insti could be enhanced by its ability
to detect HIV gp41 IgM antibodies [20].
The performance of the oral based kits was lower than the
blood based ones, especially their sensitivity and NPV which
fell below the recommended WHO performance targets.
We are aware that a few other studies in Africa have shown
good performance of these oral based kits [21–23] and their
use in self-testing is being promoted. Such a policy is also be-
ing developed in Uganda and our recommendation is to
emphasize the need to perform other confirmatory tests
based on blood assays after oral self-testing. Since all those
involved in testing were well trained we do not think this
poor performance of the oral based kits was due to the test-
ing being performed by nurse counsellors as opposed to
laboratory technician who performed the blood based RTs.
We have identified three algorithms whose cost is either
lower or within 20% the price of the current one and with bet-
ter performance. We recommend these algorithms to be
adopted by the Ministry of Health (MOH) as the national al-
gorithms for the country. The above approach gives providers
a choice of algorithms that can be used especially if there are
procurement challenges such as those we observed when one
of the kits was temporarily withdrawn. We however recognize
the challenges of moving from using one algorithm to three.
There will be a need to have training and understanding new
concepts including the possibility of interchanging the con-
firmatory and the tie breaker kits since two of the algorithms
can use these interchangeably i.e. Determine + SD Bioline +
Statpak or Determine + Statpak + SD Bioline. If the MOH
eventually decides to reduce to two algorithms these two
would be preferred since it simplifies training and procure-
ment. On the other hand, if it is recommended to stick to only
one algorithm as currently, and from the initial discussions
this appears to be the preferred option, then the algorithm to
recommend would be Determine + Statpak + SD Bioline, the
reason being this would be very easy to introduce since there
is only one change from the current algorithm, replacing
Unigold as the tie breaker with SD Bioline. Our study there-
fore provides the policy makers with a number of options.
Though the ROC for the three selected algorithms did not
significantly differ from the currently used one, the above
performance in terms of Se, Sp, NVP and PPV met the pre-
set performance requirements to guide the selection.
We also recommend that all algorithms that performed
better than the current one are made available as alternatives
for the private sector where choice is largely based on per-
formance rather than cost. Currently different test algorithms
are being used in the private sector guided by availability and
unfortunately, some of these algorithms have not been evalu-
ated locally. Our recommendation will provide the private
sector with a number of alternatives; some of these have very
high performance only limited by cost which may not be an
issue for some clients. The challenge is that these are too
many algorithms and training and QC programmes could be
difficult to implement in such situations yet they are import-
ant components of HCTand RT scaling up [24].
From our study, we propose that kits being recommended
should be used following the manufacturers criteria, scoring
both strong and WP bands as positive. When serial testing as
being proposed is followed, the performance of these kits
would be improved and the intensity of the bands would be
less of an issue. We however recognize the fact that reading/
interpretation of RT strips is subjective and depends on a
number of factors not least, the available light and the reader’s
visual acuity. There are now efforts by manufacturers to pro-
vide automated readers that would address this subjectivity.
Our study did not identify significant geographical re-
gional differences in the frequency of WP bands in
Uganda possibly ruling out a local environment factor as
responsible for these WP bands.
The screening tests recommended are very sensitive
but with low specificity. Due to this, service providers
should avoid giving final positive test results based on
the screening test results alone as often reported, which
could be false positive.
The use of highly specific confirmatory test ensures that
a confirmed positive sample is likely to be a true positive.
Table 7 Antigens and technology used in the selected kits
Kit Antigen Technology
Determine Recombinant (Rec) HIV-1
(gp120 and gp41),
Rec HIV-2 (gp36)
Lateral flow
immunochromatography
SD Bioline Rec HIV-1 (gp 41 and p24)
and RecHIV-2 (gp 36)
Lateral flow
immunochromatography
Statpak No information Lateral flow
immunochromatography
Insti Rec HIV-1 (gp 41)
and Rec HIV-2 (gp 36)
Flow through
immunochromatography
Kaleebu et al. BMC Infectious Diseases  (2018) 18:93 Page 10 of 14
With a highly specific tie-breaker any concordance positive
result with the confirmatory test would provide a definitive
result. On the other hand, a rare discordance between a tie
breaker and an equally specific confirmatory test would
warrant a client to have a repeat test after 14 days, a strat-
egy recommended by WHO [17] in high prevalence set-
tings which we propose to adopt under the new national
Algorithm. If the rate of HIV-inconclusive results is high,
additional efforts to assure quality should be made, and the
selection of assays might be reconsidered.
HIV misdiagnosis has recently been reported [25], raising
concerns about RT algorithms. Our study however on the
contrary has shown that with carefully selected RTs, we can
achieve the WHO recommended testing algorithms per-
formance. By further adopting the above additional WHO
recommendations for high HIV prevalence settings, we ex-
pect increased test results accuracy. None of our best per-
forming algorithms was tested in the Kosack study.
The rapid tests recommended had acceptable inter-
reader variability within the WHO recommended < 5% [2],
the minor differences were largely as a result of recording
the intensity of the bands as either WP or being truly posi-
tive an issue which can be minimized if we follow the man-
ufacturer’s guidelines and record all bands as positive. The
finger stick testing at the POC was performed at acceptable
standards except for one center in Masaka and this was by
one individual, as reported above, this was attributed to
poor training of this person who joined later in the study.
We therefore recommend an active training and QC
programme if we are to have an efficient HCT programme.
Since the oral based kits individually did not perform
as well as the blood based ones, they are not recom-
mended to be part of the national algorithm.
This HIV RT evaluation, has allowed our NRL to col-
lect and store specimens from different parts of Uganda
that will in future be available for QA/QC of new tests
that come on market.
We recognize that the kits evaluated are all 3rd generation
assays and currently new 4th generation tests have come on
the market [6]. The advantage of these new kits is the early
detection of recent seroconverters due to the inclusion of
the p24 antigen detection. The performance of these new
tests for the detection of acute infection are however still
questionable [5, 6]. In this evaluation, we also explored the
performance of one such kit i.e. the Alere Determine HIV-1/
2 Ag/Ab Combo (data not shown). It had a good sensitivity
equivalent to the 3rd generation kit, and a considerably bet-
ter specificity. We were however unable to evaluate its accur-
acy in the detection of early seroconverters and therefore we
could not make meaningful recommendations on its use.
Our study has a number of strengths; it is the largest
rapid test evaluation in Uganda in terms of subject num-
bers and test kits. It is the first that has followed both the
CDC/WHO recommended phase I and II approaches
which in addition to laboratory, include POC field evalua-
tions by non-laboratory workers. The study evaluated both
the blood based and three commercially available oral
based kits. Furthermore, the study followed very high QA/
QC checks supervised by a highly experienced team with
some of the laboratories used having various accreditations
such as ISO 15189 and College of American Pathologist
(CAP). The other strength of our study was that it was car-
ried out with continuous consultations with the MOH and
the C17 committee which advises on issues of HTC. Their
recommendations were therefore taken into consideration.
The study had some challenges. There were difficulties in
the procurement of some kits. As mentioned earlier, one
very good kit Medinostics HIV1/2 Gold Rapid Screen Test
was dropped because it could not be procured. The SD Bio-
line rapid HIV test was temporarily withdrawn by The U.S.
President’s Emergency Plan for AIDS Relief (PEPFAR) and
removed from the USAID list of approved rapid HIV test
kits. During the period of the evaluation and as mentioned
earlier Determine changed manufacture from Abbott to
Alere Determine, which came on market. We had to evalu-
ate this new test before moving to phase II. The study had
planned to perform inter-lab evaluation but this was not
possible due to logistical challenges. Finally, there were also
some pressures from some manufacturers and suppliers to
include their tests in the evaluation.
Like a few other studies in Africa that followed the
CDC/WHO recommendations, it was expensive and
took long to complete due to different factors including
those mentioned above.
The limitations of this study included the fact that the
criteria for a fresh blood sample may not have met the
manufacture’s recommendations for some kits investigated
in phase I of the study due to some delays in transfer of
samples from the field to the laboratory. The evaluation of
test kits using venous blood sample in phase I may not
mimic that using finger stick in the field due to the time
difference between collection and testing and also due to
the possible interference of the anticoagulant. Whereas it
was preferable to use samples from volunteers whose HIV
status was unknown and avoid selection bias, the total sam-
ple size required to collect all the HIV positives using this
approach was going to make the study very costly and
hence samples were collected from both known and un-
known HIV positive and negative study participants. We
decided to use the CDC/WHO guidelines for the sample
size as using area specific HIV prevalence resulted in a big
sample that could not be used because of budget limita-
tions. It was not logistically possible to evaluate all the 18
algorithms that performed better than the current algo-
rithm in phase II, hence the performance that we report for
fifteen of these is limited to the laboratory evaluation (phase
I). Finally, the inter observer agreement using finger stick
whole blood was not possible between the field site.
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Conclusion
In this first evaluation of a national HIV RT algorithm in
Uganda using the CDC/WHO recommended method, we
have come up with three algorithms we recommend for
public or Government procurement based on accuracy
and cost, i.e. Determine + SD Bioline + Statpak; Deter-
mine + Statpak + SD Bioline and Determine + Statpak +
Insti. If it is recommended to stick to only one algorithm
as currently, then the algorithm to recommend would be
Determine + Statpak + SD Bioline, replacing Unigold as
the tie breaker with SD Bioline. We further recommend
that all the 18 algorithms that have shown better perform-
ance than the current one are all made available to the pri-
vate sector especially where cost is not a limiting factor.
Appendix
Calculation of Algorithm Costs
The procedure below was used to estimate the cost of
each algorithm.
Algorithm Cost = Screening kit cost + Confirmatory kit
Cost + Tie breaker kit Cost.
Following National Guidelines, if a sample turns out to be
Negative on the screening test, then the cost of testing that
sample would only be equal to the screening test kit cost for a
sample. If the sample turns out to be Positive, then you would
use a confirmatory test. If the confirmatory test turns out to
be positive then the cost of test for that sample would be
equal to cost per sample for screening + confirmatory test. If,
however the screening test result is positive, and the confirma-
tory test result is negative then you would need a tie breaker.
The cost of testing such a sample would then be the.
Screening kit cost + Confirmatory kit cost + Tie Breaker
kit cost.
Example using three samples A, B, and C.
The Algorithm under review consists of Kits X (screen-
ing kit), Y (confirmatory kit) and Z (Tie Breaker).
X Costs 10 Dollars a test.
Y costs 15 dollars a test.
Z Costs 20 Dollars a test.
Sample A.
On testing Sample A using the screening kit X it turns
out NEGATIVE. Following National Guidelines, the test-
ing would be stopped and results reported. So the Total
Cost of testing Sample A would be 10 $.
Sample B.
On testing sample B using screening kit X it turns out
as POSITIVE. This requires a Confirmatory test (Y). On
testing it using Kit Y it turns out POSITIVE. The testing
would stop and results would be reported. The total cost
of testing sample B would be 10 + 15 = 25 $.
Sample C.
On testing sample C using screening kit X it turns out
as POSITIVE. This requires a Confirmatory test (Y). On
testing it using Kit Y it turns out as NEGATIVE. This
would then require a tie breaker (Z). On testing, it turns
out as NEGATIVE or POSITIVE. Then results that are
reported would be NEGATIVE or POSITIVE in conform-
ity to what the tie breaker kit result was. The cost of test-
ing sample C would be 10 + 15 + 20 = 45$.
In determining the cost of an algorithm, we need to put
into consideration the HIV prevalence in the country. While
all samples would be tested on the screening test, the number
of samples that eventually go for confirmatory and tie breaker
testing will depend on the HIV prevalence (About 7.3% if we
take this as the national average prevalence) and to a lesser
extent the sensitivity and specificity of the kits used.
Screening cost = Cost of testing all samples using the
screening kit.
Confirmatory cost = Cost of testing true positives using
the confirmatory kit + Cost of testing screening kit false
positives using the confirmatory kit-Cost of testing screen-
ing kit false negatives using the confirmatory kit.
Tie breaker cost = Cost of testing confirmatory kit
false negatives using the tie breaker kit + cost of testing
screening kit false positives using the tie breaker kit-
Cost of testing screening and confirmatory kit false
positives.
Kit costs were obtained from the USAID Source and
Origin Waiver: Procurement Information Document,
fifth Edition, 2009 and the WHO 2013 prices. This
document put the cost of Determine at $1.2, Medinos-
tics $0.85, Statpak $0.9, Unigold $1.5, Insti $4.53, and
SD Bioline $0.85.
Example 1
Suppose you want to test 10,000 samples using the
current algorithm in a population with an HIV preva-
lence of 7.3%.
The total no. of HIV positives =0.073 × 10,000 = 730.
The total no. of HIV negatives = 10,000–730 = 9270.
Using the formular above and figures in Table 1.
Screening cost = 10,000 × 1.2 = $12,000.
Confirmatory cost = (730 × 0.9) + (0.104 × 9270)
× 0.9-(0.007 × 730) × 0.9 = 1520.
Tie breaker cost = (0.012 × 730) × 1.5 + (0.104 × 9270)
× 1.5-(0.104x9270x0.016) × 1.5 = 1436.
Total cost = 12,000 + 1520 + 1436 = 14,956.
Algorithm cost per sample = 14,956/10,000 = $1.50.
Example 2
If prevalence is 30%,
Total no of HIV positives will = 0.3 × 10,000 = 3000.
Total no of negatives = 10,000–3000 = 7000.
Screening cost = 10,000 × 1.2 = $12,000.
Confirmatory cost = (3000 × 0.9) + (0.104 × 7000)
× 0.9-(0.007 × 3000) × 0.9 = 3336.
Tie breaker cost = (0.012 × 3000) × 1.5 + (0.104 × 7000)
× 1.5-(0.104x7000x0.016) × 1.5 = 1129.
Total cost = 12,000 + 3336 + 1129 = 16,465.
Algorithm cost per sample = 16,501/10,000 = $1.65.
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